Skip to main content

tebapivat

Generic: Tebapivat

tebapivat: sourced relationships with 1 company · 2 clinical trials tracked.

tebapivat evidence translation

What we can confirm

What it means

Source-backed records connect tebapivat to AGIO; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could tebapivat → AGIO affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Related indications

Sickle Cell Disease; Myelodysplastic SyndromesPotential treatment of lower-risk myelodysplastic syndrome (LR MDS) and hemolytic anemiasMyelodysplastic SyndromesSickle Cell Disease

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
AGIOS PHARMACEUTICALS, INC. (AGIO)
developer · Reported 2025-02-13 · Current development: unknownSource
Sickle Cell Disease; Myelodysplastic Syndromes
Phase 4
AGIOS PHARMACEUTICALS, INC. (AGIO)
developer · Reported 2024-02-15 · Current development: unknownSource
Potential treatment of lower-risk myelodysplastic syndrome (…
Phase 2
Clinical Trial Registry Records (2)

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease

NCT06924970Registry updated 2026-09-28·Phase 2·AGIO
Active, not recruiting

Primary endpoint: Percentage of Participants With Hb Response

InterventionalRandomizedquadruple59 enrolledStarted 2025-05Completion 2027-0520 sites · Belgium, Canada, France, Ireland…Agios Pharmaceuticals, Inc.

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes

NCT05490446Registry updated 2026-09-28·Phase 2·AGIO
Active, not recruiting

Primary endpoint: Phase 2a: Proportion of Participants With Hemoglobin (Hb) Response

Interventionalopen87 enrolledStarted 2022-11Completion 2029-0345 sites · Australia, Austria, Czechia, France…Agios Pharmaceuticals, Inc.

Frequently asked questions

Which companies have sourced relationships with tebapivat?

tebapivat has dated SEC/FDA relationship records for AGIOS PHARMACEUTICALS, INC..

How many clinical trials involve tebapivat?

BioSniper tracks 2 clinical trials involving tebapivat.